Definiens Announces Expansion to North America

03-Aug-2005

Definiens AG announced the opening of a wholly owned U.S. subsidiary, Definiens Inc., which closely follows the company's global expansion plan. This momentous growth is also due to an increased demand for Definiens' products and solutions, as well as part of an effort to continue the high level of services and support that Definiens' customers have come to expect and appreciate. Additionally, the U.S. and European offices have been undergoing an increase in staff in order to support the growing demand for the new products and solutions. To better serve its customers Definiens will open offices in Boston (Massachusetts) and Boulder (Colorado).

"Definiens is experiencing significant growth in the U.S. for its image intelligence software solutions and services," said Thomas Heydler, Definiens' CEO. "Our expansion into the United States is a major step in developing our international business. A U.S.-based branch will enable us to expand our presence in our most important market and demonstrates our commitment to our North American customers."

"Definiens is now increasingly focusing on developing the next generation of image intelligence solutions such as for high-content screening, histopathology, and diagnostics in the Life Sciences market, and for urban analysis, forestry and military/security purposes in the Geospatial market," Heydler adds. "Our new facilities in the U.S. will give us access to 'best of the best' scientific and business communities in one of the world's most innovative areas. Furthermore we will be able to strengthen our current partnerships and be closer to our growing base of North American clients."

The Company will retain its main offices in Munich (Germany) which houses its R&D and the European operations.

Other news from the department business & finance

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper